WHO ICTRP trial
Phase 2 Study of Posaconazole in Chagas Disease
EUCTR2013-000161-36-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-000161-36-ES |
|---|---|
| Public title | Phase 2 Study of Posaconazole in Chagas Disease |
| Scientific title | Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) - Phase 2 Study of Posaconazole in Chagas Disease |
| Primary sponsor | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc., |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Venezuela, Bolivarian Republic of;Mexico;Argentina;Spain;Guatemala;Peru;Chile;Colombia |
| Conditions | Chronic Chagas Disease MedDRA version: 16.0 Level: LLT Classification code 10066500 Term: Chagas disease recurrent System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Parasitic Diseases [C03] |
| Interventions | Trade Name: Noxafil Product Name: Noxafil Product Code: Noxafil Pharmaceutical Form: Oral suspension INN or Proposed INN: posaconazole Other descriptive name: POSACONAZOLE Concentration unit: mg/ml milligram(s)/millilitre Concentration… |
| Registration date | Oct 6, 2013 |
| Target size | 160 |
| Secondary IDs | P05267(MK-5592-055) |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: